| Total | $6.41M |
| Unattributed, 11/07 Pittsburgh Life Sciences Greenhouse | $200k |
| Series A, 7/09 Innovation Works Pittsburgh Life Sciences Greenhouse Ogden Capital M5Invest Partners | $1.21M |
| Series A, 1/11 Golden Seeds TMC Investment Company Ogden Capital M5Invest Partners Pittsburgh Life Sciences Greenhouse Innovation Works | $2.5M |
| Series A, 1/11 Golden Seeds M5Invest Partners Pittsburgh Life Sciences Greenhouse Innovation Works | $2.5M |
Cognition Therapeutics, Inc. is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer’s disease and other degenerative diseases of the human brain. Toxic proteins play a crucial role in a large class of disease targets, and there are currently no therapeutics available to prevent toxic protein accumulation or block their destructive effects. Cognition is founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses and proprietary medicinal chemistry that insures novel, high quality small-molecule drug candidates.
